Nonhomologous end joining key factor XLF enhances both 5-florouracil and oxaliplatin resistance in colorectal cancer.
Document Type
Journal Article
Publication Date
1-1-2019
Journal
OncoTargets and Therapy
Volume
12
Inclusive Pages
2095-2104
DOI
10.2147/OTT.S192923
APA Citation
Liu, Z., Yu, M., Fei, B., Sun, J., & Wang, D. (2019). Nonhomologous end joining key factor XLF enhances both 5-florouracil and oxaliplatin resistance in colorectal cancer.. OncoTargets and Therapy, 12 (). http://dx.doi.org/10.2147/OTT.S192923
Peer Reviewed
1
Open Access
1
COinS